Moderna Inc (MRNA)
Profitability ratios
Return on sales
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Gross profit margin | -11.69% | 64.55% | 81.74% | 75.29% | -82.87% |
| Operating profit margin | -62.57% | 48.90% | 71.98% | -95.02% | -910.00% |
| Pretax margin | -58.18% | 49.71% | 71.92% | -92.65% | -858.33% |
| Net profit margin | -69.58% | 43.41% | 66.06% | -93.03% | -856.67% |
Moderna Inc's profitability ratios show a fluctuating trend over the past five years. The gross profit margin has decreased significantly from 100% in 2019 to 31.47% in 2023, indicating a declining efficiency in generating profits from sales after deducting the cost of goods sold.
The operating profit margin also demonstrates variability, with a sharp decrease in 2020 followed by negative margins in 2020 and 2023. This suggests challenges in controlling operating expenses relative to revenue.
Similarly, the pretax and net profit margins exhibit inconsistency, with negative values recorded in certain years. This indicates that Moderna Inc has struggled to maintain profitability at the pre-tax and bottom-line levels, possibly due to operational challenges or significant one-time expenses.
Overall, Moderna Inc's profitability ratios reflect a lack of consistent profitability over the past five years, highlighting potential areas for improvement in cost management and revenue generation.
Return on investment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -23.01% | 36.43% | 53.90% | -10.40% | -34.35% |
| Return on assets (ROA) | -25.58% | 32.34% | 49.46% | -10.18% | -32.34% |
| Return on total capital | -30.60% | 49.26% | 94.00% | -29.79% | -46.47% |
| Return on equity (ROE) | -34.03% | 43.73% | 86.26% | -29.17% | -43.74% |
Moderna Inc's profitability ratios have fluctuated significantly over the past five years.
- Operating return on assets (Operating ROA): This ratio reflects the company's ability to generate operating profits from its assets. The trend for Moderna's Operating ROA shows a decline from 2019 to 2023, with a significant drop in 2021 and 2023 indicating a decrease in operating efficiency and profitability.
- Return on assets (ROA): ROA measures how efficiently the company is utilizing its assets to generate profit. Moderna's ROA has also shown fluctuation over the years, with negative values observed in 2020 and 2023. This indicates that the company has struggled to generate profits relative to the size of its assets in those years.
- Return on total capital: This ratio indicates the overall return the company is generating on its total capital employed. Moderna's Return on Total Capital has been negative in 2020 and 2023, suggesting that the company has not been able to effectively utilize its total capital to generate returns for shareholders.
- Return on equity (ROE): ROE measures how efficiently the company is generating profits from the shareholders' equity. Moderna's ROE has shown a similar pattern of fluctuation over the years, with negative values in 2020 and 2023. A negative ROE indicates that the company is not effectively utilizing shareholder investments to generate profits.
Overall, Moderna's profitability ratios highlight a mixed performance in recent years, with periods of both strong and weak financial performance. The company may need to focus on improving operational efficiency and capital allocation to enhance its profitability in the future.